L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. George Simon, an investigator at the MD Anderson Cancer Center for the Phase I study of L-DOS47 with pemetrexed and carboplatin in first …

Helix BioPharma Corp. Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has authorized a process to explore a partnership, alliance, joint development or licensing transaction of its L-DOS47 drug product candidate (the “Transaction”).  Today’s announcement …

Helix BioPharma Corp and Helix Immuno-Oncology to present at AACR in Chicago

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast …

Helix BioPharma Corp. to Present at the Biotech Showcase Conference

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Monday, January 8, 2018 at 4:30pm (PT) at Hilton San Francisco Union Square.

Helix BioPharma Corp. Signs Binding Letter of Intent for Development of New CAR-T Technologies

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the finalization of a collaborative binding letter of intent (“LOI”) with ProMab Biotechnologies, Inc. (“ProMab”) to develop chimeric antigen receptor T-cell therapy (“CAR-T”) for hematological malignances and solid tumours. The …

Helix BioPharma Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD750,600.

Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017.

Helix BioPharma Corp. Annouces Management Change

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced Steve Demas, its Chief Operating Officer, has resigned due to personal reasons.